Compare Marsh & McLennan Companies, Inc. (MRSH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Tango Therapeutics Inc. — how do they compare? Marsh & McLennan Companies, Inc. trades at $179.94 (market cap $84.47B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 22.5× Tango Therapeutics Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Tango Therapeutics Inc. for 0 Days on average.
| MRSH | TNGX | |
|---|---|---|
Market Cap | $84.47B | $3.75B |
Volume | 3,662,234 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $203.85 | $32.90 |
52-Week Low | $157.32 | $7.50 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $105.15B | $2.77B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $178.40, up 1.05% today, with a bullish technical signal and recent earnings beats. The stock shows strong fundamentals with a P/E of 21.61, net income margin of 14.24%, and consistent revenue growth to $27.0B in 2025. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) enhances its advisory services, while analyst consensus is a 'Hold' with a $202.71 price target. Cash flow remains positive at $486M in 2025, supporting dividend payments.
Outlook is cautiously optimistic; the stock offers growth potential from strategic acquisitions and solid profitability, but risks include high P/B of 5.56 and competitive pressures. Investors should weigh the 13.6% upside to the consensus target against overbought RSI levels and margin compression risks in 2026 forecasts.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
